Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$1.1 billion.

  • Centessa Pharmaceuticals' Retained Earnings fell 2765.8% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 2765.8%. This contributed to the annual value of -$988.7 million for FY2024, which is 3131.13% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.1 billion for Q3 2025, which was down 2765.8% from -$1.1 billion recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Retained Earnings high stood at -$440.2 million for Q1 2022, and its period low was -$1.1 billion during Q3 2025.
  • Moreover, its 4-year median value for Retained Earnings was -$752.9 million (2023), whereas its average is -$773.4 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Retained Earnings plummeted by 4825.08% in 2023, and later plummeted by 2120.75% in 2024.
  • Centessa Pharmaceuticals' Retained Earnings (Quarter) stood at -$601.9 million in 2022, then dropped by 25.1% to -$752.9 million in 2023, then plummeted by 31.31% to -$988.7 million in 2024, then decreased by 13.29% to -$1.1 billion in 2025.
  • Its Retained Earnings stands at -$1.1 billion for Q3 2025, versus -$1.1 billion for Q2 2025 and -$1.0 billion for Q1 2025.